RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

CardioGenics Holdings Revenue 2024

CardioGenics Holdings Revenue

0 USD

CardioGenics Holdings Dividend yield

Ticker

CGNH

ISIN

US14160X2036

WKN

A1C048

In 2024, CardioGenics Holdings's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.

The CardioGenics Holdings Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2015--
2014--
2013--
20120-9230,77
20110.01-1351,35
2010--
20090.02-600,00
20080.1883,33
20070.265,00
20060.1747,06
20050.2437,50
20040.25-8,00
20030.39-79,49
20020.63-82,54
20011-620,00
20001.04-681,73
19990.836,25
19980.9388,17
19970.9584,21

CardioGenics Holdings Aktienanalyse

What does CardioGenics Holdings do?

The company CardioGenics Holdings Inc. is headquartered in Mississauga, Canada, and is a leading company in the field of cardiovascular disease diagnostics. The company was founded in 1997 by Walter Witoshkin, who continues to serve as CEO today. CardioGenics' business model is based on the development and marketing of solutions for fast, reliable, and cost-effective diagnosis of cardiovascular diseases. The focus is especially on the diagnosis of heart attacks and heart failure. To achieve these goals, CardioGenics has developed various divisions. The most important division is the production of in-vitro diagnostics (IVD). These are tests that are performed based on blood samples, enabling doctors to make a quick and easy diagnosis. Another important area of CardioGenics is the development of diagnostics based on immunassays. Antibodies are used to identify specific proteins in the blood that indicate a certain disease. This allows early predictions about the risk of cardiovascular diseases. In addition to the development of diagnostics, CardioGenics is also active in the field of research and development. The company works closely with academic institutions and research partners to develop and market innovative solutions in the field of diagnostics. CardioGenics' products include various IVD tests specifically developed for the diagnosis of cardiovascular diseases. One of the most important products is the QL Care Analyzer, a fully automated system for the rapid determination of Troponin I, a protein released in the blood during heart attacks. Another important product of CardioGenics is the Myo9 test. This test is an immunassay that allows doctors to determine the risk of cardiovascular diseases in certain patient groups. The test is mainly used for patients with diabetes, as they have an increased risk of cardiovascular diseases. Furthermore, CardioGenics also offers various services such as training and user support for its products. The company works closely with customers to provide them with the best possible support in the application of IVD tests and other diagnostic products. In recent years, CardioGenics has expanded its business internationally and launched its products in various countries. The company also has a strong presence at leading scientific conferences and trade fairs to showcase its products and services and share its expertise in the field of cardiovascular diagnostics. In summary, CardioGenics is an established company in the field of cardiovascular disease diagnostics. With a wide range of diagnostic products and a strong focus on research and development, the company is well positioned to continue growing and strengthen its presence in the international market. CardioGenics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding CardioGenics Holdings's Sales Figures

The sales figures of CardioGenics Holdings originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing CardioGenics Holdings’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize CardioGenics Holdings's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in CardioGenics Holdings’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about CardioGenics Holdings Stock

How much revenue did CardioGenics Holdings generate this year?

CardioGenics Holdings has achieved a revenue of 0 USD this year.

How much was the turnover of the company CardioGenics Holdings compared to the previous year?

The revenue of CardioGenics Holdings has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of CardioGenics Holdings?

The revenue of CardioGenics Holdings is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of CardioGenics Holdings measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of CardioGenics Holdings so important for investors?

The revenue of CardioGenics Holdings is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does CardioGenics Holdings pay?

Over the past 12 months, CardioGenics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CardioGenics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of CardioGenics Holdings?

The current dividend yield of CardioGenics Holdings is .

When does CardioGenics Holdings pay dividends?

CardioGenics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CardioGenics Holdings?

CardioGenics Holdings paid dividends every year for the past 0 years.

What is the dividend of CardioGenics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CardioGenics Holdings located?

CardioGenics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von CardioGenics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CardioGenics Holdings from 5/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/22/2024.

When did CardioGenics Holdings pay the last dividend?

The last dividend was paid out on 5/22/2024.

What was the dividend of CardioGenics Holdings in the year 2023?

In the year 2023, CardioGenics Holdings distributed 0 USD as dividends.

In which currency does CardioGenics Holdings pay out the dividend?

The dividends of CardioGenics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CardioGenics Holdings

Our stock analysis for CardioGenics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CardioGenics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.